Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans

By Carsten T. Charlesworth, Priyanka S. Deshpande, D. Dever, Beruh T. Dejene, N. Gomez‐Ospina, Sruthi Mantri, Mara Pavel-Dinu, J. Camarena, Kenneth I. Weinberg, M. Porteus. bioRxiv, 2018

856 citations recorded by the source corpus.

Subfields: Molecular Biology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/a41e84ffeefd1229a48b9af04647090840b37263

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Joy Y. Wang
2. Ansuman T. Satpathy
3. Howard Y. Chang
4. Frederic D. Bushman
5. Jennifer A. Doudna
6. C. June
7. Pedro J. Batista
8. Feng Zhang

In Public Health, Environmental and Occupational Health

1. Jennifer A. Doudna

Citations in the corpus

• CRISPR technology: A decade of genome editing is only the beginning (2023, background): “In some cases, DNA cargo can permit prolonged expression of Cas9, but this increases the probability of off-target effects and immunogenic reactions (170, 171).”
• CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future (2020, background): “A major caveat is pre-existing immunity in humans against 2 of these orthologs—SpCas9 and SaCas9, leaving CjCas9 as the only current option for this cohort of patients.”
• CRISPR-engineered T cells in patients with refractory cancer (2020, background): “The potential rejection of infused cells due to preexisting immune responses to Cas9 (28, 29) does not appear to be a barrier to the application of this promising technology.”